ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,421 to 2,440 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)22 of 2,142

25 of 1,044

-1.4 points

-2.5 to -0.4

3,186NCT04649151

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)2 of 2,142

9 of 1,044

-0.8 points

-1.5 to -0.3

3,186NCT04649151

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Apixaban 2.5mg BID vs Enoxaparin 30 mg SC Injection q 12 Hours: serious adverse events123 of 1,596

123 of 1,588

-0.0 points

-1.9 to 1.8

3,184NCT00371683

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke69 of 1,591

89 of 1,592

-1.3 points

-2.8 to 0.3

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure83 of 1,591

100 of 1,592

-1.1 points

-2.7 to 0.6

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time to First AE Leading to Permanent Trial Product Discontinuation184 of 1,591

104 of 1,592

5.0 points

3.0 to 7.0

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time From Randomisation to All-cause Death23 of 1,591

45 of 1,592

-1.4 points

-2.4 to -0.4

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke61 of 1,591

76 of 1,592

-0.9 points

-2.4 to 0.5

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke13 of 1,591

17 of 1,592

-0.3 points

-1.0 to 0.5

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction37 of 1,591

35 of 1,592

0.1 points

-0.9 to 1.2

3,183NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: deaths from any cause23 of 1,591

45 of 1,591

-1.4 points

-2.4 to -0.4

3,182NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Oral Semaglutide vs Placebo: serious adverse events301 of 1,591

358 of 1,591

-3.6 points

-6.4 to -0.8

3,182NCT02692716

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Intervention vs Control: deaths from any cause3 of 1,552

1 of 1,629

0.1 points

-0.2 to 0.5

3,181NCT04060667

Wireless Physiologic Monitoring in Postpartum Women

Intervention vs Control: serious adverse events6 of 1,552

12 of 1,629

-0.4 points

-0.9 to 0.2

3,181NCT04060667

Wireless Physiologic Monitoring in Postpartum Women

Arm 1: MOVE OUT vs Arm 2: MOVE!: serious adverse events32 of 1,571

29 of 1,598

0.2 points

-0.8 to 1.2

3,169NCT01339390

MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)

Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Who Report Thoughts of Self Harm - Patient Health Questionnaire (PHQ-9) in All Practices39 of 1,067

116 of 2,102

-1.9 points

-3.3 to -0.3

3,169NCT05110014

Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety

Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Screening Positive for Fall Risk at Home in All Practices907 of 1,067

1,692 of 2,102

4.5 points

1.7 to 7.2

3,169NCT05110014

Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety

Primary Care Office Visits (Pre Intervention) vs Primary Care Office Visits (Post Intervention): Number of Participants Screening Positive for Intimate Partner Violence in All Practices10 of 1,067

310 of 2,102

-13.8 points

-15.4 to -12.2

3,169NCT05110014

Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety

CDI Cases vs CDI Negative Controls: The Number of Cases of CDI103 of 103

0 of 3,050

100.0 points

96.4 to 100.0

3,153NCT03503474

COMBACTE-CDI Understanding the Burden of C. Difficile Infection

M-M-R II ® vs Placebo: Number of Participants With Symptomatic COVID-19 at 60 Days24 of 1,607

19 of 1,545

0.3 points

-0.6 to 1.1

3,152NCT04333732

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=122"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=122

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04649151-6fef783b",
        "title": "Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)",
        "summary": "22 of 2142 against 25 of 1044; risk difference -1.4 points, 95% interval -2.5 to -0.4; NCT04649151, A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",
        "record": "/library/comparisons/NCT04649151-6fef783b",
        "nct_id": "NCT04649151",
        "kind": "outcome",
        "participants": 3186,
        "risk_difference": {
          "value": -0.013675585176599376,
          "lower": -0.025369903275453656,
          "upper": -0.004387420578445144
        },
        "group_1": "22 of 2,142",
        "group_2": "25 of 1,044",
        "difference": "-1.4 points",
        "interval": "-2.5 to -0.4",
        "trial_title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19"
      },
      {
        "id": "NCT04649151-b1799155",
        "title": "Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)",
        "summary": "2 of 2142 against 9 of 1044; risk difference -0.8 points, 95% interval -1.5 to -0.3; NCT04649151, A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",
        "record": "/library/comparisons/NCT04649151-b1799155",
        "nct_id": "NCT04649151",
        "kind": "outcome",
        "participants": 3186,
        "risk_difference": {
          "value": -0.007686982839112656,
          "lower": -0.015398441409124462,
          "upper": -0.002921491341910506
        },
        "group_1": "2 of 2,142",
        "group_2": "9 of 1,044",
        "difference": "-0.8 points",
        "interval": "-1.5 to -0.3",
        "trial_title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=123",
  "request_id": "SBkE-I3rallAjn2x"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?